Spritam (Levetiracetam) Patent Expiration, LOE Window & CMS Spending

Spritam (Levetiracetam) by Aprecia: FDA Orange Book LOE 2034-03-14, 32 AB generics, $3.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAprecia
FDA Application & PathwayN207958 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-14
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors32
2024 CMS Total Public Spend$3.0M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$1.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.1% 2-yr change)